London's Boltz secures $110 M Series A, led by Bessemer, to fast‑track drug discovery with AI models
drug-discovery startup
| Source: Techmeme | Original article
London AI drug‑discovery startup Boltz, a MIT spin‑out, secured a $110 million Series A led by Bessemer, following a $28 million seed round in 2025.
London‑based AI startup Boltz announced a $110 million Series A financing round, led by venture firm Bessemer. The funding follows a $28 million seed round raised in 2025 and marks the latest influx of capital into the burgeoning field of artificial‑intelligence‑driven drug discovery. Boltz, which spun out of MIT before relocating to London, is building proprietary AI models aimed at accelerating the identification and optimisation of therapeutic candidates.
The sizeable Series A underscores growing investor confidence that machine‑learning tools can shorten the traditionally lengthy and costly drug‑development timeline. By automating early‑stage tasks such as target validation and molecular design, Boltz hopes to reduce the time and expense required to bring new medicines to clinical testing. The round also positions the company alongside other well‑funded AI biotech ventures that have recently attracted large sums of capital, suggesting a broader market shift toward data‑centric R&D approaches.
What to watch next is how Boltz deploys the new capital. Key indicators will include the recruitment of scientific and engineering talent, the formation of partnerships with pharmaceutical firms or research institutions, and the progression of any AI‑generated candidates into pre‑clinical or early‑stage trials. Investors and industry observers will also be keen to see whether the company can demonstrate measurable speed‑ups or cost reductions that validate its AI‑first strategy, potentially setting a benchmark for the next wave of biotech innovation.
Sources
Back to AIPULSEN